Ads
related to: sickle cell disease treatment- Treatment Journey
See the treatment journey
Step by step.
- Resources
Downloadable HCP brochure
and more professional resources.
- Mechanism of Action Video
Watch an MOA video on the
official HCP website.
- About The Therapy
The science behind the disease
and this treatment option.
- Stay Informed
Sign up to receive updates
as they become available.
- Treatment Journey Video
See the treatment journey
video on the HCP website.
- Treatment Journey
Search results
Results From The WOW.Com Content Network
December 8, 2023 at 1:19 PM. The Food and Drug Administration on Friday approved a powerful treatment for sickle cell disease, a devastating illness that affects more than 100,000 Americans, the ...
Sickle cell is the most common disease to receive approval for gene therapy treatment, following decades of development and years of approvals for therapy for people with rarer conditions.
Diseases such as sickle cell disease for which a person's normal phenotype or cell function may be restored in cells that have the disease by a normal copy of the gene that is mutated, may be a good candidate for gene therapy treatment. The risks and benefits related to gene therapy for sickle cell disease are not known.
By comparison, research earlier this year showed medical expenses for current sickle cell treatments, from birth to age 65, add up to about $1.6 million for women and $1.7 million for men.
Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Voxelotor is the first hemoglobin oxygen-affinity modulator. Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients.
Sickle cell disease consists of several subtypes; however, the Haemoglobin type C (HbSC) subtype carries the gravest prognosis for sickle cell retinopathy and vision changes. [2] Regular retinal examinations can aid in early detection and treatment, thus reducing the impact of the condition and the risk of vision loss.
Hydroxycarbamide. Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and cervical cancer. [2] [3] In sickle-cell disease it increases fetal hemoglobin and decreases the number of attacks. [2] It is taken by mouth.
In 2023, the U.S. FDA approved five gene therapies, including a sickle cell disease treatment from Vertex Pharmaceuticals and CRISPR Therapeutics that uses the latter's gene editing technology.
Ads
related to: sickle cell disease treatment